FI964033A - Förfaranden för behandling av sjukdom genom att använda Sertoli-celler och allografter eller xenografter - Google Patents

Förfaranden för behandling av sjukdom genom att använda Sertoli-celler och allografter eller xenografter Download PDF

Info

Publication number
FI964033A
FI964033A FI964033A FI964033A FI964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A
Authority
FI
Finland
Prior art keywords
cells
treating
sertoli cells
disease
allografts
Prior art date
Application number
FI964033A
Other languages
English (en)
Finnish (fi)
Other versions
FI964033A0 (sv
FI120670B (sv
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of FI964033A0 publication Critical patent/FI964033A0/sv
Publication of FI964033A publication Critical patent/FI964033A/sv
Application granted granted Critical
Publication of FI120670B publication Critical patent/FI120670B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI964033A 1994-04-13 1996-10-08 Farmaceutisk komposition innefattande Sertoli-celler och användning därav FI120670B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
US21169594 1994-04-13
US9504565 1995-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts

Publications (3)

Publication Number Publication Date
FI964033A0 FI964033A0 (sv) 1996-10-08
FI964033A true FI964033A (sv) 1996-12-12
FI120670B FI120670B (sv) 2010-01-29

Family

ID=22787974

Family Applications (2)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (sv) 1994-04-13 1996-10-08 Farmaceutisk komposition innefattande Sertoli-celler och användning därav
FI20085733A FI120696B (sv) 1994-04-13 2008-07-18 Metoden för ökning av cellernas återhämtning och delning

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20085733A FI120696B (sv) 1994-04-13 2008-07-18 Metoden för ökning av cellernas återhämtning och delning

Country Status (12)

Country Link
US (3) US5725854A (sv)
EP (1) EP0755258B1 (sv)
JP (1) JPH09512015A (sv)
AT (1) ATE212230T1 (sv)
AU (1) AU715177B2 (sv)
CA (1) CA2187803C (sv)
DE (1) DE69525151T2 (sv)
DK (1) DK0755258T3 (sv)
ES (1) ES2169128T3 (sv)
FI (2) FI120670B (sv)
NO (1) NO320713B1 (sv)
WO (1) WO1995028167A1 (sv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003736B1 (ru) * 1995-02-08 2003-08-28 Яманучи Юроп Б.В. Лекарственная форма для перорального введения, содержащая бета-лактамный антибиотик
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
WO1996028174A1 (en) * 1995-03-13 1996-09-19 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
KR20010033834A (ko) * 1998-01-02 2001-04-25 타이탄 파마슈티칼스 인코퍼레이티드 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DK1126858T3 (da) * 1998-11-06 2010-03-01 Sertoli Technologies Inc Produktion af en biologisk faktor og skabelse af et immunologisk privilegeret miljø ved anvendelse af genetisk ændrede Sertoliceller
EP1435220B1 (en) * 1998-12-15 2006-08-16 Universidad Nacional Autonoma de Mexico Process and device for facilitating the implantation of biological material
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
AU780366B2 (en) 2000-01-20 2005-03-17 Diatranz Otsuka Limited Preparation and xenotransplantation of porcine islets
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
AU9118201A (en) 2000-09-20 2002-04-02 Islet Sheet Medical Llc Improved methods for fabrication of thin sheet bio-artificial organs
BRPI0209552B1 (pt) * 2001-05-11 2016-05-10 Johnson & Johnson dispositivo de modulação de imunidade e método para fabrica-lo
ATE535601T1 (de) * 2001-09-28 2011-12-15 Diabcell Pty Ltd Züchtung von fremdtransplantationsmaterial in kultur
AP2004003113A0 (en) * 2002-02-22 2004-09-30 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
AU2003238760B2 (en) * 2003-06-24 2008-07-31 Diatranz Otsuka Limited Porcine islets cultured with porcine sertoli cells for xenotransplantation
EP1648380B1 (en) * 2003-07-03 2015-04-08 Sertoli Technologies, LLC Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
KR20070085223A (ko) 2004-07-29 2007-08-27 유니버시티 오브 마이애미 세포 치료를 위한 하이브리드 장치
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
WO2007089572A2 (en) * 2006-01-26 2007-08-09 John Constance M Proliferative primary human sertoli cell cultures and their applications
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2009105278A2 (en) 2008-02-21 2009-08-27 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
MX2012002440A (es) 2009-08-28 2012-06-19 Sernova Corp Metodos y dispositivos para el transplante de celulas.
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
WO2019079384A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System ADMINISTRATION DEVICES
WO2020223670A1 (en) 2019-05-01 2020-11-05 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
NO964342D0 (no) 1996-10-11
AU2289395A (en) 1995-11-10
CA2187803C (en) 1999-09-28
EP0755258B1 (en) 2002-01-23
JPH09512015A (ja) 1997-12-02
CA2187803A1 (en) 1995-10-26
FI964033A0 (sv) 1996-10-08
US5759534A (en) 1998-06-02
FI120670B (sv) 2010-01-29
DE69525151D1 (de) 2002-03-14
DE69525151T2 (de) 2002-08-14
NO320713B1 (no) 2006-01-23
US5843430A (en) 1998-12-01
ES2169128T3 (es) 2002-07-01
EP0755258A1 (en) 1997-01-29
WO1995028167A1 (en) 1995-10-26
DK0755258T3 (da) 2002-05-13
FI20085733A (sv) 2008-07-18
NO964342L (no) 1996-12-13
ATE212230T1 (de) 2002-02-15
AU715177B2 (en) 2000-01-20
US5725854A (en) 1998-03-10
FI120696B (sv) 2010-01-29

Similar Documents

Publication Publication Date Title
FI964033A (sv) Förfaranden för behandling av sjukdom genom att använda Sertoli-celler och allografter eller xenografter
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
HUT76659A (en) A method of enhancing cellular production molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
SE0000305L (sv) Förfarande och anordning vid superstruktur till implantat
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DK0698109T3 (da) Genoverføring til pancreasepithelceller
DK0643775T3 (da) Quinonderivater til forbedring af cellebioenergi
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA200100195A1 (ru) Ингибирование реакции "трансплантат против хозяина"
FI951511A (sv) Användning av IL-10 till förebyggande eller behandling av insulinberoende diabetes mellitus
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
DK0883406T3 (da) Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed
TR199802706T2 (xx) Bir bitki hastal���n�n iyile�tirilmesi i�in y�ntem.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO20012214D0 (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
DK1207905T3 (da) Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
ATE253378T1 (de) Xenogene transplantation

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120670

Country of ref document: FI

MA Patent expired